# Boston Scientific (BSX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BSX
## Company Profile
- Ticker: BSX
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 51.19 USD
- Market cap: 70869414934.72 USD
- Last updated: 2026-08-11
## Business Overview
### Global Medical Technology Platform
Boston Scientific is a global medical technology company with products spanning cardiovascular care, endoscopy, urology, neuromodulation, interventional oncology, respiratory care, and gastrointestinal medicine. Its portfolio centers on high-performance devices and minimally invasive therapies designed to improve clinical outcomes while reducing the burden on healthcare systems.
### Electrophysiology Franchise
Electrophysiology is a major innovation area for Boston Scientific. The FARAPULSE pulsed field ablation system has demonstrated advantages over antiarrhythmic drug therapy in persistent atrial fibrillation, while the FARAFLEX Mapping and PFA Catheter extends the platform toward integrated cardiac mapping and ablation.
### Coronary, Structural Heart, and Embolization
The company also continues to broaden its interventional portfolio. Recent activity includes positive pivotal evidence for the SEISMIQ coronary intravascular lithotripsy catheter, FDA clearance of the TruSelect 2.6 Microcatheter, and strategic exposure to the SIEGEL transcatheter aortic valve replacement system through MiRus.
### MedSurg Businesses
Outside cardiovascular care, Boston Scientific’s MedSurg segment provides technologies for endoscopy, urology, neuromodulation, and other minimally invasive procedures. This business mix reduces dependence on any single therapeutic area and gives the company multiple channels for new-product adoption.
### Diversified Operating Base
Boston Scientific operates through its Cardiovascular and MedSurg segments, with additional businesses including Urology and Neuromodulation. The company expands its platform through internal R&D, strategic investments, and acquisition options, including its investment in MiRus and potential rights to acquire the SIEGEL TAVR business.
## Why The Stock Is Moving

Following the latest company update, “Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results”, BSX closed up 2.33% at $50.46 on Aug 10, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Enrollment has begun in the pivotal FARADIGM trial evaluating the safety and effectiveness of the FARAFLEX Mapping and PFA Catheter in patients with paroxysmal or persistent atrial fibrillation.

## Recent News
- 2026-08-10 12:00 EST — [Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results](https://biopharmsignal.com/news/BSX/boston-scientific-announces-participation-in-wells-fargo-21st-annual-healthcare--85639cd7) — Source: Boston Scientific
- 2026-07-29 10:30 EST — [Boston Scientific announces results for second quarter 2026](https://biopharmsignal.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2026-cbac35ee) — Source: Boston Scientific
- 2026-05-19 10:31 EST — [FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints](https://biopharmsignal.com/news/BSX/fracture-ide-trial-of-the-boston-scientific-seismiqtm-4ce-coronary-intravascular-lithotripsy-catheter-meets-primary-safety-and-effectiveness-endpoints) — Source: Boston Scientific
- 2026-05-18 11:00 EST — [Boston Scientific enters into $2 billion accelerated share repurchase agreement](https://biopharmsignal.com/news/BSX/boston-scientific-enters-into-2-billion-accelerated-share-repurchase-agreement) — Source: Boston Scientific
- 2026-05-18 10:30 EST — [Boston Scientific announces strategic investment in MiRus LLC](https://biopharmsignal.com/news/BSX/boston-scientific-announces-strategic-investment-in-mirus-llc) — Source: Boston Scientific